These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32672006)

  • 1. Recent trends in antipsychotic polypharmacy in the treatment of schizophrenia.
    Yasui-Furukori N; Shimoda K
    Neuropsychopharmacol Rep; 2020 Sep; 40(3):208-210. PubMed ID: 32672006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic drug interactions with newer antipsychotics: a comparative review.
    Spina E; de Leon J
    Basic Clin Pharmacol Toxicol; 2007 Jan; 100(1):4-22. PubMed ID: 17214606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in antipsychotic prescriptions for Japanese outpatients during 2006-2012: a descriptive epidemiological study.
    Kochi K; Sato I; Nishiyama C; Tanaka-Mizuno S; Doi Y; Arai M; Fujii Y; Matsunaga T; Ogawa Y; Furukawa TA; Kawakami K
    Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):642-656. PubMed ID: 28266090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotic polypharmacy in the treatment of schizophrenia in China and Japan.
    Qiu H; He Y; Zhang Y; He M; Liu J; Chi R; Si T; Wang H; Dong W
    Aust N Z J Psychiatry; 2018 Dec; 52(12):1202-1212. PubMed ID: 30309245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the individual safe correction of antipsychotic agent polypharmacy in Japanese patients with chronic schizophrenia: validation of safe corrections for antipsychotic polypharmacy and the high-dose method.
    Yamanouchi Y; Sukegawa T; Inagaki A; Inada T; Yoshio T; Yoshimura R; Iwata N
    Int J Neuropsychopharmacol; 2014 Dec; 18(5):. PubMed ID: 25522380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison.
    Roh D; Chang JG; Kim CH; Cho HS; An SK; Jung YC
    Aust N Z J Psychiatry; 2014 Jan; 48(1):52-60. PubMed ID: 23671214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001-2009).
    Xiang YT; Wang CY; Si TM; Lee EH; He YL; Ungvari GS; Chiu HF; Yang SY; Chong MY; Tan CH; Kua EH; Fujii S; Sim K; Yong KH; Trivedi JK; Chung EK; Udomratn P; Chee KY; Sartorius N; Shinfuku N
    Pharmacopsychiatry; 2012 Jan; 45(1):7-12. PubMed ID: 21989602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QTc interval in patients with schizophrenia receiving antipsychotic treatment as monotherapy or polypharmacy.
    Elliott A; Mørk TJ; Højlund M; Christensen T; Jeppesen R; Madsen N; Viuff AG; Hjorth P; Nielsen JC; Munk-Jørgensen P
    CNS Spectr; 2018 Aug; 23(4):278-283. PubMed ID: 28659221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotic Polypharmacy and Its Relation to Metabolic Syndrome in Patients With Schizophrenia: An Egyptian Study.
    Aly El-Gabry DM; Abdel Aziz K; Okasha T; Azzam H; Okasha A
    J Clin Psychopharmacol; 2018 Feb; 38(1):27-33. PubMed ID: 29210867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evolution of antipsychotic switch and polypharmacy in natural practice--a longitudinal perspective.
    Tsutsumi C; Uchida H; Suzuki T; Watanabe K; Takeuchi H; Nakajima S; Kimura Y; Tsutsumi Y; Ishii K; Imasaka Y; Kapur S
    Schizophr Res; 2011 Aug; 130(1-3):40-6. PubMed ID: 21624824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipsychotic Polypharmacy: A Dirty Little Secret or a Fashion?
    Lin SK
    Int J Neuropsychopharmacol; 2020 Feb; 23(2):125-131. PubMed ID: 31867671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipsychotic Polypharmacy in Older Adult Asian Patients With Schizophrenia: Research on Asian Psychotropic Prescription Pattern.
    Dong M; Zeng LN; Zhang Q; Yang SY; Chen LY; Sim K; He YL; Chiu HF; Sartorius N; Tan CH; Chong MY; Shinfuku N; Lin SK; Ng CH; Ungvari GS; Xiang YT
    J Geriatr Psychiatry Neurol; 2019 Nov; 32(6):304-311. PubMed ID: 31480982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation.
    Stahl SM; Grady MM
    Curr Med Chem; 2004 Feb; 11(3):313-27. PubMed ID: 14965234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using an Integrated Care Pathway for Late-Life Schizophrenia Improves Monitoring of Adverse Effects of Antipsychotics and Reduces Antipsychotic Polypharmacy.
    Abdool PS; Supasitthumrong T; Patel K; Mulsant BH; Rajji TK
    Am J Geriatr Psychiatry; 2019 Jan; 27(1):84-90. PubMed ID: 30396766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews.
    Ijaz S; Bolea B; Davies S; Savović J; Richards A; Sullivan S; Moran P
    BMC Psychiatry; 2018 Sep; 18(1):275. PubMed ID: 30176844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polypharmacy and psychotropic drug loading in patients with schizophrenia in Asian countries: Fourth survey of Research on Asian Prescription Patterns on antipsychotics.
    Yang SY; Chen LY; Najoan E; Kallivayalil RA; Viboonma K; Jamaluddin R; Javed A; Hoa DTQ; Iida H; Sim K; Swe T; He YL; Park Y; Ahmed HU; De Alwis A; Chiu HF; Sartorius N; Tan CH; Chong MY; Shinfuku N; Lin SK
    Psychiatry Clin Neurosci; 2018 Aug; 72(8):572-579. PubMed ID: 29761577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The trend for megadose polypharmacy in antipsychotic pharmacotherapy: a prescription survey conducted by the psychiatric clinical pharmacy research group].
    Yoshio T
    Seishin Shinkeigaku Zasshi; 2012; 114(6):690-5. PubMed ID: 22844820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of Antipsychotic Polypharmacy Versus Monotherapy in a Nationwide Cohort of 61,889 Patients With Schizophrenia.
    Taipale H; Tanskanen A; Tiihonen J
    Am J Psychiatry; 2023 May; 180(5):377-385. PubMed ID: 36945825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: A systematic review and meta-analysis.
    Matsui K; Tokumasu T; Takekita Y; Inada K; Kanazawa T; Kishimoto T; Takasu S; Tani H; Tarutani S; Hashimoto N; Yamada H; Yamanouchi Y; Takeuchi H
    Schizophr Res; 2019 Jul; 209():50-57. PubMed ID: 31182319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the trends of polypharmacy and high-dose prescriptions in Japan.
    Shinfuku N
    Asia Pac Psychiatry; 2022 Mar; 14(1):e12488. PubMed ID: 34519433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.